Informationen:
Fehler:
ID
15274
Beschreibung
Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00237211
Link
https://clinicaltrials.gov/show/NCT00237211
Stichworte
Versionen (1)
- 24.05.16 24.05.16 -
Hochgeladen am
24. Mai 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Postmenopausal Women With Advanced Breast Cancer NCT00237211
Eligibility Postmenopausal Women With Advanced Breast Cancer NCT00237211
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Postmenopausal Women With Advanced Breast Cancer NCT00237211
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
breast cancer
Item
patients with histologically documented breast cancer.
boolean
C0678222 (UMLS CUI [1])
hormone receptor status
Item
patients with hormone receptor (er and/or pgr) status of positive or unknown
boolean
C0019929 (UMLS CUI [1])
amenorrheic
Item
patients who have been amenorrheic for the preceding 12 months or more.
boolean
C0002453 (UMLS CUI [1])
age
Item
patients who are 20 years or older and younger than 75 years.
boolean
C0001779 (UMLS CUI [1])
therapeutic procedures
Item
patients with a history of postoperative adjuvant therapy or a history of endocrine therapy with tamoxifen for the treatment of progression or recurrence of the lesion. the endocrine therapy, however, should not exceed one regimen.
boolean
C0087111 (UMLS CUI [1])
progressing lesions
Item
patients with progressing lesions.
boolean
C0221198 (UMLS CUI [1,1])
C0205329 (UMLS CUI [1,2])
C0205329 (UMLS CUI [1,2])
sufficient organ function
Item
patients with sufficient organ function to evaluate the safety
boolean
C1254358 (UMLS CUI [1,1])
C0205410 (UMLS CUI [1,2])
C0205410 (UMLS CUI [1,2])
performance status
Item
patients whose performance status (ps) is classified in 0～2.
boolean
C1520224 (UMLS CUI [1])
ID.9
Item
patients who have no residual effects from previous treatments
boolean
malignant disease
Item
patients with other concurrent or previous malignant disease (excluding uterine carcinoma in-situ).
boolean
C0006826 (UMLS CUI [1])
hypercalcemia and uncontrollable cardiac disease
Item
patients with hypercalcemia and uncontrollable cardiac disease (including a history of serious cardiac disease)
boolean
C0020437 (UMLS CUI [1])
C0018799 (UMLS CUI [2])
C0018799 (UMLS CUI [2])
aromatase inhibitor
Item
patients who have previously received aromatase inhibitor.
boolean
C0593802 (UMLS CUI [1])
lymphangitis-type lung metastasis or symptomatic brain metastasis
Item
patients who have lymphangitis-type lung metastasis or symptomatic brain metastasis.
boolean
C0153676 (UMLS CUI [1])
C0220650 (UMLS CUI [2])
C0220650 (UMLS CUI [2])
other inclusion criteria
Item
other protocol-defined inclusion / exclusion criteria may apply.
boolean
C1512693 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])